Findings

What do systematic reviews say?

5 questions · 8 findings · 4 reviews · ENT

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 5 · 62.5%Low 3 · 37.5%Moderate 0 · 0%High 0 · 0%

Betahistine vs placebo/no treatment

Improvement in vertigo frequency · Ménière’s disease

It is very uncertain whether betahistine changes improvement in vertigo frequency compared with placebo/no treatment (very low certainty).

2 findings from 1 review

Systemic pharmacological interventions for Ménière’s disease 2023 · Cochrane Headline outcomes only
RR 1.5 [0.98, 2.29]
1 study · 70 participants
Very low
Systemic pharmacological interventions for Ménière’s disease 2023 · Cochrane Headline outcomes only
RR 1.11 [0.93, 1.32]
1 study · 62 participants
Very low

Diuretic vs placebo/no treatment

Improvement in vertigo frequency · Ménière’s disease

It is very uncertain whether diuretic changes improvement in vertigo frequency compared with placebo/no treatment (very low certainty).

1 finding from 1 review

Systemic pharmacological interventions for Ménière’s disease 2023 · Cochrane Headline outcomes only
RR 1.69 [1.13, 2.53]
1 study · 70 participants
Very low

Intratympanic corticosteroids vs placebo/no treatment

Improvement in vertigo frequency · Ménière’s disease

Intratympanic corticosteroids showed no clear difference in improvement in vertigo frequency compared with placebo/no treatment (low certainty).

2 findings from 1 review

Intratympanic corticosteroids for Ménière’s disease 2023 · Cochrane Headline outcomes only
RR 1 [0.92, 1.1]
2 studies · 60 participants
Low
Intratympanic corticosteroids for Ménière’s disease 2023 · Cochrane Headline outcomes only
RR 1.03 [0.87, 1.23]
2 studies · 58 participants
Low

Intratympanic gentamicin vs no treatment/placebo

Improvement in vertigo frequency · Ménière’s disease

It is very uncertain whether intratympanic gentamicin changes improvement in vertigo frequency compared with no treatment/placebo (very low certainty).

2 findings from 1 review

Intratympanic gentamicin for Ménière’s disease 2023 · Cochrane Headline outcomes only
RR 33 [2.15, 507]
1 study · 32 participants
Very low
Intratympanic gentamicin for Ménière’s disease 2023 · Cochrane Headline outcomes only
RR 1.63 [0.98, 2.69]
1 study · 22 participants
Very low

Positive pressure therapy vs placebo

Improvement in vertigo frequency · Ménière’s disease

Positive pressure therapy showed no clear difference in improvement in vertigo frequency compared with placebo (low certainty).

1 finding from 1 review

Positive pressure therapy for Ménière’s disease 2023 · Cochrane Headline outcomes only
RR 1.19 [0.82, 1.71]
1 study · 77 participants
Low